Author: Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Sebastian Burgstaller-Muehlbacher; Lars Pache; Paul P. De Jesus; Mitchell V. Hull; Max Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina Herbert; Tu-Trinh Nguyen; Yuan Pu; Courtney Nguyen; Andrey Rubanov; Luis Martinez-Sobrido; Wen-Chun Liu; Lisa Miorin; Kris M. White; Jeffrey R. Johnson; Christopher Benner; Ren Sun; Peter G. Schultz; Andrew Su; Adolfo Garcia-Sastre; Arnab K. Chatterjee; Kwok-Yung Yuen; Sumit K. Chanda
Title: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals Document date: 2020_4_17
ID: 1fgnfh62_64
Snippet: Inhibition of cathepsin L activity has been previously shown to efficiently suppress SARS-CoV-1 infection 78 . We found ONO 5334 (a cathepsin K inhibitor) and VBY-825 (a reversible cathepsin protease inhibitor) to inhibit SARS-CoV-2 infection in a dosedependent manner, however additional studies will be required to determine if their antiviral activities are due to inhibiting proteolysis of viral or host cellular proteins. ONO 5334 harbored an an.....
Document: Inhibition of cathepsin L activity has been previously shown to efficiently suppress SARS-CoV-1 infection 78 . We found ONO 5334 (a cathepsin K inhibitor) and VBY-825 (a reversible cathepsin protease inhibitor) to inhibit SARS-CoV-2 infection in a dosedependent manner, however additional studies will be required to determine if their antiviral activities are due to inhibiting proteolysis of viral or host cellular proteins. ONO 5334 harbored an antiviral EC50 of ~500 nM, which is in range of a previously reported 85 % activity observed at 100 nM in an osteoclast-mediated bone resorption assay 80 .
Search related documents:
Co phrase search for related documents- additional study and cellular protein: 1
- additional study and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- antiviral activity and cathepsin inhibition: 1, 2, 3, 4
- antiviral activity and cathepsin protease: 1
- antiviral activity and cellular protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- antiviral activity and host viral cellular protein: 1, 2
- antiviral activity and previously report: 1, 2
- antiviral activity and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- antiviral activity and SARS infection inhibit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- bone resorption and SARS infection: 1
- cathepsin inhibition and inhibit proteolysis: 1
- cathepsin inhibition and SARS infection: 1, 2, 3
- cathepsin protease and cellular protein: 1, 2, 3
- cathepsin protease and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- cathepsin protease and SARS infection inhibit: 1, 2
- cathepsin protease inhibitor and SARS infection: 1
- cellular protein and host viral cellular protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- cellular protein and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- cellular protein and SARS infection inhibit: 1
Co phrase search for related documents, hyperlinks ordered by date